Galecto begins third phase II trial

The first patient has now received a dose of Galecto's drug candidate GB1211 in a crucial phase 1b/2a trial meant to assess its efficacy in treating liver cirrhosis.

Hans Schambye, president and CEO at Galecto. | Photo: Henriette Dan Bonde / PR

With the first dose administered, Galecto has now begun a third phase II trial – specifically a 1b/2a trial. The substance is being tested as a treatment for liver cirrhosis.

This makes it the third of the company's drug candidates to enter a mid-phase trial.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs